Related Experiment Video

Updated: May 15, 2026

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors
12:03

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors

Published on: June 7, 2016

[Angiotensin-2 type 1 receptors (AT1R) and cancers]

Thibault Dolley-Hitze1, Grégory Verhoest, Florence Jouan

  • 1Service de néphrologie, CHU Pontchaillou, 2, rue Henri-Le-Guilloux, 35033 Rennes, France.

Nephrologie & Therapeutique
|January 22, 2013
PubMed

Insights

Antagonists of angiotensin-2 receptors and inhibitors of angiotensinogen converting enzyme show potent anticancer properties in experimental research, despite conflicting epidemiological data. Further prospective studies are needed to clarify their clinical use in cancer treatment.

Area of Science:

  • Pharmacology
  • Oncology
  • Cardiovascular Medicine

Context:

  • Conflicting epidemiological studies suggest a potential cancer risk associated with angiotensin-2 receptor antagonists (ARBs) and angiotensin-converting enzyme inhibitors (ACEIs).
  • Existing meta-analyses and retrospective studies are limited by design, potentially introducing bias and failing to adequately assess antitumor effects.
  • There is a lack of prospective studies to definitively resolve the debate surrounding the oncological impact of these widely used cardiovascular medications.

Purpose:

  • To critically review and analyze recent literature on the association between ARBs and ACEIs and cancer.
  • To reconcile conflicting findings from epidemiological studies with robust experimental evidence.
  • To explore the potential antitumoral properties of ARBs and ACEIs.

Summary:

  • Experimental research consistently demonstrates significant antitumoral effects of ARBs and ACEIs, including direct antiproliferative activity and inhibition of neo-angiogenesis in preclinical models.
  • These drugs have shown potent effects on tumor cell cultures and animal models, suggesting a direct role in cancer suppression.
  • Despite conflicting epidemiological data, experimental findings strongly support the potential therapeutic value of these agents in oncology.

Impact:

  • The findings suggest that ARBs and ACEIs may hold future clinical utility as adjuncts to conventional chemotherapy in cancer treatment.
  • This review highlights the need for well-designed prospective clinical trials to validate the anticancer potential of these drugs.
  • Understanding the dual role of these cardiovascular drugs in cancer could lead to novel therapeutic strategies and improved patient outcomes.

More Related Videos

Subcutaneous Angiotensin II Infusion using Osmotic Pumps Induces Aortic Aneurysms in Mice07:21

Subcutaneous Angiotensin II Infusion using Osmotic Pumps Induces Aortic Aneurysms in Mice

Published on: September 28, 2015

Live Cell Imaging and 3D Analysis of Angiotensin Receptor Type 1a Trafficking in Transfected Human Embryonic Kidney Cells Using Confocal Microscopy09:51

Live Cell Imaging and 3D Analysis of Angiotensin Receptor Type 1a Trafficking in Transfected Human Embryonic Kidney Cells Using Confocal Microscopy

Published on: March 27, 2017

Related Concept Videos

Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Adrenergic Receptors: ɑ Subtype01:31

Adrenergic Receptors: ɑ Subtype

Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase C—inositol-1,4,5-trisphosphate...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...